Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 5/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.36 |
| ▸ | PDE2A | O00408 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL361749 | 0.95 | AKT1 (0.40) | AKT1EGLN2PGRGPR119DRD2 | |
| SCHEMBL14161428 | 0.95 | EGLN2 (0.38) | AKT1EGLN2PGRGPR119DRD2 | |
| SCHEMBL3052055 | 0.88 | EGLN2 (0.38) | EGLN2PGRGPR119DRD2ABCB1 | |
| SCHEMBL538971 | 0.87 | PGR (0.39) | EGLN2PGRGPR119DRD2ABCB1 | |
| SCHEMBL13152804 | 0.87 | PGR (0.39) | EGLN2PGRGPR119DRD2ABCB1 | |
| SCHEMBL15255661 | 0.87 | PGR (0.39) | EGLN2PGRGPR119DRD2ABCB1 | |
| SCHEMBL24838757 | 0.86 | AKT1 (0.41) | AKT1DRD2PDE2A | |
| SCHEMBL13256652 | 0.84 | PGR (0.37) | AKT1EGLN2PGRGPR119DRD2 | |
| SCHEMBL18551335 | 0.82 | MIF (0.46) | AKT1DRD2PDE2A | |
| SCHEMBL24838756 | 0.82 | AKT1 (0.41) | AKT1DRD2PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692085-A2 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20260015314-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2026-01-15 | — | — | US | disclosed |
| EP-4041388-B1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-12391641-B2 | Prostaglandin EP4 receptor antagonist compounds | Nxera Pharma UK Limitied (GB) | 2025-08-19 | — | — | US | disclosed |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025064718-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2022268066-A1 | PROTEIN DEGRADATION AGENT | 苏州开拓药业股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-20220411364-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2022-12-29 | — | — | US | disclosed |
| US-20220411364-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2022-12-29 | — | — | US | disclosed |
| EP-4041388-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | Heptares Therapeutics Limited (GB) | 2022-08-17 | — | — | EP | disclosed |
| EP-2649061-B1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-05-13 | — | — | EP | disclosed |
| US-8828987-B2 | Pyridine amide derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-09-09 | — | — | US | disclosed |
| US-8828987-B2 | Pyridine amide derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-09-09 | — | — | US | disclosed |
| US-20130261100-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2013-10-03 | — | — | US | disclosed |
| US-20130261100-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2013-10-03 | — | — | US | disclosed |
| US-8541407-B2 | Substituted benzo-pyrido-triazolo-diazepine compounds | ARQULE, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541407-B2 | Substituted benzo-pyrido-triazolo-diazepine compounds | ARQULE, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| WO-2012076063-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM S.P.A. (IT) | 2012-06-14 | — | — | WO | disclosed |
| US-20110245236-A1 | Substituted Benzo-Pyrido-Triazolo-Diazepine Compounds | ARQULE, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245236-A1 | Substituted Benzo-Pyrido-Triazolo-Diazepine Compounds | ARQULE, INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245236-A1 | Substituted Benzo-Pyrido-Triazolo-Diazepine Compounds | BRD4, PDXK, THPO | AKT1 3428/4885EGLN2 1575/4885PGR 202/4885 |
| US-12391641-B2 | Prostaglandin EP4 receptor antagonist compounds | PTGER1, PTGER4, PTGER2 | AKT1 3031/4885EGLN2 968/4885PGR 190/4885 |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | AKT1 51/4885EGLN2 1886/4885PGR 3151/4885 |
| US-20130261100-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, CNR1 | AKT1 2734/4885EGLN2 838/4885PGR 180/4885 |
| US-20260015314-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | PTGER4, PTGER1, PTGER3 | AKT1 3101/4885EGLN2 3067/4885PGR 329/4885 |
| US-20220411364-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | PTGER1, PTGER4, PTGER2 | AKT1 3031/4885EGLN2 968/4885PGR 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.